news

Jan 24, 2017

U.K. weighs drug rationing as NHS England's budget tightens: report Patients in the U.K. face yet another barrier to access as a tough budget situation has forced the country’s healthcare system to consider rationing costly drugs. Among them are medicines from Johnson & Johnson, Merck and Roche. Beginning in Apr...

Jan 17, 2017

US FDA accepts Mylan’s BLA for proposed trastuzumab product Biocon and Mylan have announced acceptance of the latter’s biologics licence application (BLA) by the US Food and Drug Administration (FDA) for MYL-1401O, a proposed biosimilar trastuzumab. Mylan’s MYL-1401O is indicated to treat certain HER2-positive breas...

Jan 05, 2017

Greek prosecutors raid Novartis offices, disclose wide-ranging probe into bribery allegations Greek officials announced that they are investigating Novartis for bribery in the wake of local media reports raising questions about the company. It is the fourth set of bribery allegations against the Swiss drugmaker to g...

Jan 03, 2017

Sanofi sues Novo over 'misleading' Tresiba marketing materials Sanofi has sued Novo over the Danish drugmaker’s marketing materials for Tresiba, alleging that they falsely claimed Sanofi’s competing products—blockbuster Lantus and follow-up Toujeo—won’t be available to many U.S. patients down the line. The pharma gi...

Dec 15, 2016

CDC study reveals Zika virus replicates in foetal brain and placentas Study conducted by the US Centers for Disease Control and Prevention (CDC) has revealed that the Zika virus replicates in the brain tissues of infants with microcephaly and persists in foetal brains and placentas of women who suffered pregnancy lo...

Nov 23, 2016

Novartis Buys Blood Disease Drug Maker for $665mn Novartis has acquired Selexys Pharmaceuticals, a drug maker specializing in development of therapeutics in certain hematologic and inflammatory disorders. Novartis exercised its right to acquire Selexys following receipt of results of the SUSTAIN study, a Phase II tr...

Oct 25, 2016

Boston Biomedical starts phase III study of Napabucasin Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stemness pathways, announced dosing of the first patient in CanStem303C, a new global phase III study investigating napabucasin in combination with standard of...

Oct 18, 2016

Merck launches Biosimilars Clarified, a new online educational resource about biosimilar medicines for patients and the healthcare community Merck has announced the launch of Biosimilars Clarified, a new educational website for patients, caregivers and the healthcare community that is designed to provide clear, conc...